Abstract While the specific trigger of Parkinson Disease (PD) in most patients is unknown, considerable evidence suggests that the neuroinflammatory response makes an essential contribution to the neurodegenerative process. Drugs targeting metabotropic glutamate receptors (mGlu receptors), 7 Transmembrane (7TM) spanning/G protein coupled receptors that bind glutamate, are emerging as therapeutic targets for PD and may have antiinflammatory properties. ADX88178 is novel potent, selective, and brain-penetrant positive allosteric modulator of the mGlu4 which is under evaluation for treatment of PD and other neurological disorders. We used microglia cultured from mouse brain to determine if ADX88178 had direct effects on the inflammatory responses of these cells. We studied both microglia from wild type and Grm4 knock out mice. We found that activation of mGlu 4 with ADX88178 attenuated LPS-induced inflammation in primary microglia, leading to a decrease in the expression of TNFα, MHCII, and iNOS, markers of proinflammatory responses. These effects were absent in microglia from mice lacking mGlu 4 . These results demonstrate a cell-autonomous anti-inflammatory effect of ADX88178 mediated mGlu 4 activation on microglia, and suggest that this drug or similar activators or potentiators of mGlu 4 may have disease-modifying as well as symptomatic effects in PD and other brain disorders with an inflammatory component.
Introduction
Parkinson disease (PD) is a common neurodegenerative movement disorder. PD is associated with accumulation of aggregated forms of the protein alpha-synuclein (α-syn) in dopaminergic neurons in the substantia nigra pars compacta (SNpc) and in other parts of the brain. One consequence of α-syn accumulation is an increase in microglial activation, which leads to the production of inflammatory cytokines and chemokines and T-cell infiltration (Lang and Lozano 1998) . While the specific trigger of PD is in most patients unknown, considerable evidence suggests that neuroinflammatory responses, similar to those observed upon microglial activation, make an essential contribution to the neurodegenerative process.
Inflammation in the CNS can be initiated by microglia, the resident immune cells of the central nervous system, in response to neuronal damage and other molecular triggers (Harms et al. 2013) . A characteristic early response of microglia is production of the inflammatory mediator tumor necrosis factor alpha (TNFα). This leads to downstream effects including enhanced expression of induced nitric oxide synthase (iNOS) and major histocompatibility complex II (MHCII) expression. Increased MHCII expression is an important step in α-syn mediated neurodegeneration, and decreased MHCII expression reduces the toxicity of α-syn (Harms et al. 2013) .
Metabotropic glutamate receptors (mGlu) are 7 transmembrane spanning/G protein coupled receptors that bind glutamate, and drugs targeting mGlu receptors are emerging as therapeutic targets for PD. mGlu 4 is a heteroreceptor found on the terminals of GABAergic striatopallidal axons, and activation or potentiation of mGlu 4 using small molecule positive allosteric modulators (PAMs) reduces excessive GABA release from these terminals and induces anti-Parkinsonian effects in a range of model systems (Valenti et al. 2003; Marino et al. 2003; Lopez et al. 2007; Bennouar et al. 2013; Beurrier et al. 2009; Engers et al. 2011; Jones et al. 2012; Jones et al. 2011; Niswender et al. 2008; Le Poul et al. 2012; East et al. 2010 ). An advantage of PAMs over glutamate-site agonists is that these small molecules often have greater selectivity and improved pharmacokinetics compared to conventional orthosteric agonists; for example, ADX88178, the PAM used in this study, has high selectively for mGlu 4 over other molecular targets (Le Poul et al. 2012) .
Recent work has revealed that mGlu 4 orthosteric agonists and PAMs may also have anti-inflammatory effects. Microglia express mGlu 4 receptor protein, and treatment with of microglial/neuronal cultures in vitro with the orthosteric mGlu 4 activators (L)-2-amino-4-phosphono-butyric acid (L-AP-4) or (R,S)-phosphonophenylglycine (RSPPG) reduces neuronal apoptosis resulting from microglial activation (Taylor et al. 2003) . In vivo, activation of mGlu 4 with orthosteric agents in neurotoxin-based rat models of PD preserves motor function and reduces dopamine neuron loss (Zhou et al. 2003; Betts et al. 2012) . Additionally, targeting mGlu 4 with a PAM in a 6-hydroxydopamine rat model of PD results in decreased levels of inflammatory markers, in addition to providing significant protection against dopamine neuron loss and preservation of motor function (Betts et al. 2012) . Together, these data suggest that mGlu 4 PAMs could have important effects on both the short-term symptoms and the long-term progression of PD.
The present study sought to examine several key issues with respect to the anti-inflammatory effects of the mGlu 4 PAM ADX88178 in PD model systems: 1) does ADX88178 have cell-autonomous effects on the inflammatory responses of brain microglia, and 2) are the anti-inflammatory effects of ADX88178 the result of specific interaction with the mGlu 4 receptor? Results of our study indicate that treatment of primary microglial cells with ADX88178 attenuates lipopolysaccharide (LPS)-induced inflammation, characterized by reduced TNFα levels and decreased MHCII and iNOS expression. Anti-inflammatory effects of ADX88178 were not observed in microglia with genetic deletion of the mouse Grm4 gene. These data support a cell-autonomous effect of ADX88178 on brain microglia, mediated by interaction with the mGlu 4 receptor. The ability of ADX88178 to reduce inflammation as well as improve circuit function in PD models suggests that it along with other similar mGlu 4 PAMs may be valuable symptomatic and disease-modifying agents for human PD.
Materials and Methods

Mouse Model and Reagents
Wild-type (mGlu4 +/+ ), and knockout mice lacking the Grm4 gene (mGlu4
) in C57Bl/6 background were purchased from the Jackson Laboratories. (Strain 8815915) Animals were maintained in a UAB Animal Care Facility. All animal studies were performed following approved guidelines of the Institutional Animal Care and Use Committee. Breeding pairs were used to obtain neonates from both WT and mGlu 4 KO mouse colonies. Homozygous knockout status for the Grm4 gene was confirmed by genomic PCR. ADX88178 was synthesized at Vanderbilt as described in (Le Poul et al. 2012; Yin et al. 2013) . Primary antibodies used in the study were rat antimouse MHCII and iNOS from eBioscience. Biotinylated secondary antibody (anti-rat) and Alexa Fluor 488-Streptavidin were purchased from Jackson Immuno Laboratories. An enzyme-linked immunosorbent assay kit for mouse TNFα was purchased from R&D Systems (CA).
Microglia Extraction
Primary microglia were isolated from WT and mGlu 4 KO mice on postnatal days 0-2 as described by previously published protocols (Harms et al. 2013 ). The brains were isolated, the meninges were removed, and the cells were allowed to dissociate at 37°C for 10 min with periodic agitation. Mixed glial populations were plated and cultured for 11 days or until confluent. Upon confluency, microglia were isolated from the astrocyte bed by a mechanical shaking method in which culture flasks are placed in a cell shaker for 45 min at 195 rpm at 37°C. Prior to treatment, microglia from WT and mGlu 4 KO mice were plated in chamber slides at a density of 100,000 cells/well and allowed to adhere for 1 h in serum-free and glutamate-free DMEM/F12 nutrient mixture (Sigma).
Microglia Treatment with mGlu 4 Activators
After adhesion to the chamber slides, microglia from WT and mGlu4 KO microglia pre-treated with 1 nM, 10 nM, 100 nM ADX88178, or 100 nM L-AP4. Each treatment was performed in quadruplicate. Thirty minutes after treatment with ADX88178 or L-AP4, 100 ng/mL LPS was added to the cultures and the cells were incubated at 37°C for an additional 24 h. At the end of the 24 h treatment period, media was collected and analyzed for TNFα, and the cells were for iNOS and MHC II expression by immunocytochemistry.
Enzyme-Linked Immunosorbent Assay for Measurement of TNFα
To measure the amount of soluble TNFα produced by microglia following treatments, supernatants were collected from cultured cells and assayed using a TNFα DuoSet ELISA kit according to the guidelines of the manufacturer (R&D Systems). Culture supernatants were diluted with reagent diluent in a 1:5 ratio in accordance with kit instructions. Fluorescence was quantified using a microplate reader at 450 nM and analyzed using GraphPad software.
Immunocytochemistry Analysis for iNOS and MHCII Expression
After harvesting media for the TNFα measurement, the treated microglia were fixed with 2 % PFA and stained for iNOS and MHCII using the primary and secondary antibodies mentioned previously (Harms et al. 2012 ). The MHCII staining was identified using a biotinylated goat-anti-rat IgG secondary antibody at 1:500 dilution. Alexa Fluor 488 conjugated streptavidin was used at 1:500 dilution for detection.
Imaging and Quantification
A Leica TCS-SP5 laser-scanning confocal microscope was used to capture images as previously described (Harms et al. 2013) . Images were exported and processed using ImageJ. For antigen processing and presentation, immunofluorescence from four representative confocal images was quantified using ImageJ software. The corrected total cell fluorescence was quantified using the following equation: Integrated density (area of selected cell × mean fluorescence of background readings).
Results
LPS-induced TNFα is attenuated by ADX88178 treatment
To characterize the TNFα response in our system, microglial cells from C57BL/6 mice were either treated with LPS for 24 h or untreated and cultured in serum-and glutamate-free medium in which glutamate concentrations were undetectable. Replicates treated with DMSO, the vehicle for subsequent studies with ADX88178, were also included. TNFα levels were measured from culture supernatants using an ELISA assay. We observed a marked enhancement of TNFα after LPS treatment of microglial cells. There was also no effect observed of DMSO vehicle on LPS-induces TNFα production (Fig. 1) .
Next, we determined if pretreatment of microglia with ADX88178 would attenuate inflammatory responses induced by 100 ng/mL LPS treatment. Microglia were pretreated with 1, 10 or 100 nM ADX88178 or 100 nM LAP4 for 30 min followed by LPS treatment for 24 h prior to collecting culture supernatant for ELISA measurement of TNFα levels. We found that that pre-treatment with ADX88178 and LAP4 both significantly attenuated LPS-induced TNFα levels (Fig. 1A) . As little as 1 nM of ADX88178 was sufficient to inhibit TNFα, and was as effective at concentrations of 10 and 100 nM (p < 0.01, one-way ANOVA with a Tukey's post hoc test). mGlu 4 Specificity of the Anti-Inflammatory Effect of ADX88178
We evaluated the specificity of the anti-inflammatory effect of ADX88178 using microglia from animals with genetic deletion of the Grm4 gene. We cultured microglial cells from mGlu 4 KO mice and treated them with LPS as described above. This produced marked enhancement of TNFα production, but neither ADX88178 nor LPS inhibited the TNFα response in the KO microglia (Fig. 1B) .
Effects of ADX88178 on MHCII in LPS-Stimulated Microglia
TNFα signaling is an important component of the inflammatory response, but another key function of microglial cells is antigen presentation, mediated by MHCII. To determine if activation of mGlu 4 on microglial cells also leads to alterations in MHCII expression, microglia from WT and mGlu 4 KO mice were pretreated for 45 min with ADX88178 and then stimulated with LPS for 24 h. Based on the potency of the ADX88178 compound in the TNF assay, this experiment was performed with 1 nM, 10 nM, and 100 nM ADX88178. The cells were then fixed and stained for immunocytochemical detection. MHCII expression was determined using confocal microscopy and quantified with ImageJ software. As shown in Fig. 2A , we found that LPS led to a marked enhancement of MHCII staining in WT microglia. There was a significant decrease (p < 0.001, one-way ANOVA with a Tukey's post hoc test) in MHCII expression when microglia from WT mice were pretreated with ADX88178 prior to LPS stimulation. Similar pretreatment of microglia from mGlu 4 KO mice showed that ADX88178 treatment did not alter MHCII expression in the KO cells (Fig. 2B) , confirming the specificity of attenuation by ADX88178 through mGlu 4 .
Pre-Treatment of Microglia with ADX88178 Decreases iNOS Levels
An additional function of activated microglia is upregulation of pro-oxidant enzymes, including inducible nitric oxide synthase (iNOS). In particular, iNOS production is associated with elevated levels of reactive oxygen species (ROS) and nitric oxide (NO) (Zhang et al. 2005; Li et al. 2010) . To determine if modulation of mGlu 4 activity by a PAM affects iNOS level, microglia from WT and mGlu 4 KO mice were treated with ADX88178 following LPS activation. iNOS measurement after 24 h in culture demonstrated a significant decrease in microglia from WT mice (Fig. 2D, E) but not from mGlu 4 KO mice (Fig. 2F ).
Discussion
In this study, we found that the mGlu 4 PAM ADX88178 is anti-inflammatory, decreases MHC II and iNOS expression, and decreases TNFα release in microglia from WT mice, while none of these effects are observed using microglia from mGlu 4 KO mice. This suggests that the ADX88178 has broad anti-inflammatory effects on microglia that are mediated by the mGlu 4 receptor protein.
One goal of this study was to determine whether the effect of mGlu 4 agonists on microglia were cell-autonomous. Our data demonstrate clearly that activation of mGlu 4 has a direct anti-inflammatory effect on brain-derived microglial cells. Of course, this does not preclude the existence of additional antiinflammatory effects mediated indirectly. It will be important to determine whether anti-inflammatory effects of mGlu 4 agonists, such as those observed in 6-OHDA treated rats, are due solely to effects on microglia (Betts et al. 2012) , or whether there are also effects of mGlu 4 activation on other components of the immune system.
To activate the immune response in microglia, we have used LPS. This is a specific activator of toll-like receptor 4 (TLR4), which produces rapid activation of microglia via nuclear factor kappa B-induced cytokine and chemokine release. LPS is useful as a probe for TLR4 signaling, but there is also some evidence which connects the actions of LPS directly to the pathophysiology of PD. A large body of experimental work shows that LPS can induce prominent degeneration of dopaminergic neurons when administered directly into the brain (Fleegler 1987) . There is also evidence that mutations in the gene for leucinerich repeat kinase 2 (LRRK2), the most common monogenic cause of human PD, strongly modulate the response of microglia to LPS (Moore et al. 1986 ). It will be important to study the effects of mGlu activation with ADX88178 and other PAMs on other triggers for activation of microglia.
Anti-inflammatory properties of mGlu receptor other than mGlur 4 have also been reported. Activation of mGlu 5 plays a role in modulating neuronal cell death, significantly reduces microglial activation in response to LPS as measured by TNFα and iNOS levels, and decreases neuroinflammation. (Byrnes et al. 2009 ) Group 1 mGlu receptors have also been shown to mediate inflammation-induced sensitization to neuronal excitotoxicity in neonatal and adult neurons across species, suggesting a promising direction for the field using mGlu receptors as therapeutic targets for neurodegenerative disorders (Degos et al. 2013) .
Activators of mGlur 4 are of special interest in PD because they can modulate the circuit abnormalities produced by dopamine deficiency, and have direct therapeutic benefit on motor function. The basis for this action is the localization of mGlur 4 receptors on the presynaptic terminals of neurons arising in the striatum and projecting to the globus pallidus (Bradley et al. 1999) . This projection constitutes the indirect Fig. 1 a WT TNF ELISA following 1 nM, 10 nM, and 100 nM ADX and 100nM L-AP4 pretreatment and 100 ng/mL LPS treatment shows decreased levels of TNF output in response to LPS and PAM treatment, p<0.01, one-way ANOVA with a Tukey's post hoc test. b mGlu4 KO TNF ELISA shows no significant response to LPS and ADX treatment p= not significant, one-way ANOVA with a Tukey's post hoc test pathway of striatal outflow, and in this location mGlur 4 receptors act as heteroreceptors, modulating the release of GABA from striatopallidal terminals (Valenti et al. 2003) . The effect of mGluR4 activation is to reduce GABA release from these synapses, and since overactivity of the striatopallidal pathway is believed to contribute to parkinsonism, activation of the Fig. 2 a Images of MHCII stained WT microglia following 100ng/mL LPS and 1 nM, 10 nM, and 100 nM ADX treatment taken with confocal microscopy at 63x with 2x zoom. b Immunofluorescence from four representative confocal images of each sample was quantified using ImageJ software. The corrected total cell fluorescence was quantified using the following equation: Integrated density (area of selected cell × mean fluorescence of background readings) showing decreased WT MHCII expression in response to 100ng/mL LPS and 1 nM, 10 nM, and 100 nM ADX treatment, p<0.01, one-way ANOVA with a Tukey's post hoc test and c no significant decrease in mGluR4 KO MHCII expression, p= no significance, one-way ANOVA with a Tukey's post hoc test. d Images of iNOS stained WT microglia following 100ng/mL LPS and 1 nM, 10 nM, and 100 nM ADX treatment taken with confocal microscopy at 63x with 2x zoom. e Immunofluorescence from four representative confocal images of each sample was quantified using ImageJ software. The corrected total cell fluorescence was quantified using the following equation: Integrated density (area of selected cell × mean fluorescence of background readings) showing decreased WT iNOS expression in response to 1 nM, 10 nM, and 100 nM ADX pretreatment and 100 ng/mL LPS treatment, p<0.01, one-way ANOVA with a Tukey's post hoc test and f no significant change in mGluR4 KO iNOS expression, p= no significance, one-way ANOVA with a Tukey's post hoc test mGlur 4 terminals was predicted to have therapeutic benefit. Indeed, mGlur 4 agonists were shown to have marked antiparkinson benefit in reserpinized rodents (Marino et al. 2003) and to directly modulate firing of globus pallidus neurons in non-human primates (Bogenpohl et al. 2013) . As a result of these findings, there are active programs seeking to bring mGlur 4 activators in to clinical trials in human PD (Mueller et al. 2012; Johnson et al. 2009) .
In this study, we have focused on ADX88178, a novel mGlur 4 PAM. Unlike direct agonists of glutamate receptors, most of which act as glutamate analogs and bind directly to the ligand-binding site, mGlur 4 PAMs bind to a distinct allosteric site, allowing more specificity. ADX88178 is a nextgeneration mGlur 4 PAM which is potent, selective, and orally bioavailable (Kalinichev et al. 2014) . It is effective in rodent models of parkinsonism (Le Poul et al. 2012) , and is considered a prototype for compounds that will advance to clinical testing.
Microglia have been shown to play a role in a range of neurodegenerative disorders other than PD. Since mGlur 4 activation is a novel mechanism that targets microglia to achieve anti-inflammatory effects through a novel signaling pathway, mGlur 4 may also be of utility in other disorders where microglial activation is a significant contributor to the disease state.
Collectively, the results of the present study provide evidence that ADX88178, and likely other PAMs targeting mGlu 4 , can act directly on microglial mGlu 4 receptors to suppress inflammatory responses. Drugs of this class may be particularly useful in human PD because they may offer both symptomatic effects through circuit modulation as well as additive neuroprotective effects by attenuating pro-inflammatory immune mechanisms associated with PD progression.
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